Vertex Thrombectomy System Shows Clinical Efficacy
Jupiter Endovascular reports success in the SPIRARE II trial for treating pulmonary embolism patients.
Updated on Oct. 20, 2026 in Stroke
Live Poll
Do you believe new medical technology typically leads to better long-term health outcomes for patients?
Jupiter Endovascular released results from its SPIRARE II trial, finding the Vertex thrombectomy system achieved hemodynamic normalization in 50 percent of patients. The trial successfully met its primary and secondary endpoints with a major adverse event rate of 2.4 percent.
Why it matters
The study provides a comprehensive invasive hemodynamic profile to assess patient recovery, highlighting a significant reduction in pulmonary pressure and resistance. This data suggests a promising alternative for treating pulmonary embolism without the need for adjunctive thrombolytics.
The SPIRARE II trial evaluated 123 patients across 19 study sites, recording a mean procedure time of 28.5 minutes. Data showed mean pulmonary artery pressure decreased by 29 percent and total pulmonary vascular resistance dropped by 26 percent.
The players
Jupiter Endovascular
This medical technology company focuses on developing advanced catheter-based systems for treating cardiovascular disease.
The details
The Vertex system utilizes a single catheter to navigate the heart and stabilize within pulmonary arteries, allowing for invasive hemodynamic profiling. Following the procedure, the percentage of patients suffering from severe or very severe dyspnea fell from 58 percent at baseline to 3 percent at 30 days.
Timeline
The trial met its primary and secondary endpoints within a 48-hour timeframe.
Patients experienced sustained symptom improvement 30 days post-procedure.
Jupiter Endovascular announced the publication of the trial results on October 19, 2026.
The Big Picture
This study contributes to the ongoing evolution of minimally invasive cardiovascular care, extending the scope of the SPIRARE II trial protocols. It marks a departure from traditional reliance on adjunctive thrombolytics in treating pulmonary embolisms.
Patients may benefit from a procedure that avoids the use of adjunctive thrombolytics, potentially reducing complication risks. The reduction in dyspnea suggests a faster return to normal daily physical activity for those suffering from severe pulmonary issues.
The takeaway
The Vertex system demonstrates significant clinical promise by normalizing pulmonary pressure while maintaining a low adverse event profile. Physicians may find this approach particularly relevant for patients who require effective intervention while avoiding the risks associated with thrombolytic medication.
Further reading
For additional context on vascular interventions, visit the Stroke section.
Source note: This article includes information reported by DAIC.
Live Poll
Do you believe new medical technology typically leads to better long-term health outcomes for patients?
